• About Us
  • Our Approach
    • Discovery Platform
  • Pipeline
    • HMBD-001
    • HMBD-002
    • HMBD-501
  • News
  • Careers

What are you looking for?

Hummingbird Bioscience
Hummingbird Bioscience
Hummingbird Bioscience
  • About Us
  • Our Approach
    • Discovery Platform
  • Pipeline
    • HMBD-001
    • HMBD-002
    • HMBD-501
  • News
  • Careers

HER3-addicted tumors: how biotechs are closing in

by hbs-admin on 9 August, 2022 in News, News - 2022

<< Back to News

HER3-addicted tumors: how biotechs are closing in

9 August, 2022

The elusive HER3, known to drive aggressive cancers, may finally be toppled by once-abandoned antibody drugs.

VIEW NEWS FEATURE

<< Back to News

Previous Reading
Journal for ImmunoTherapy of Cancer: Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner.
Next Reading
Hummingbird Bioscience to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Leave a Reply Cancel reply

You must be logged in to post a comment.

Hummingbird Bioscience

TMC Innovation
2450 Holcombe Blvd, Suite X
Houston, TX 77021

The Galen
61 Science Park Road, #06-15/24,
Singapore 117525

For general enquiries, please contact contact@hummingbirdbio.com

For career enquiries, please contact careers@hummingbirdbio.com

For business development opportunities, please contact bd@hummingbirdbio.com


Hummingbird Bioscience Twitter Hummingbird Bioscience Twitter Hummingbird Bioscience LinkedinHummingbird Bioscience Linkedin Hummingbird Bioscience YouTube Hummingbird Bioscience YouTube
Subscribe to our updates
Registered Company No: 201505192N
PRIVACY POLICY | © 2022 Hummingbird Bioscience

Subscribe to our updates

    *indicates required

    GDPR Marketing Permissions

    *Please select all the ways you would like to hear from Hummingbird Bioscience:

    You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website. For questions about this mailing list, please email communications@hummingbirdbio.com

    We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.